Labiotech.eu

News and Trends 13 Nov 2017

World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance

This week marks the WHO’s World Antibiotic Awareness Week. We had a look at some of the best work being done by biotechs to fight resistance. An estimated 154 million prescriptions for antibiotics are written each year, but up to 30% are unnecessary. The World Health Organization has set up World Antibiotic Awareness Week to tackle this. This year’s theme is […]

November 13, 2017 - 3 minutesmins - By Alex Dale

News and Trends 13 Nov 2017

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […]

November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Nov 2017

British Biotech Gets PRIME Designation for its Brittle Bones Drug

The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. It was set up by Denise Scots-Knight, one of our top women entrepreneurs, in 2015 and already has a market cap […]

November 13, 2017 - 1 minutemin - By Alex Dale

Top 5 Things to Know About Immunotherapies – A Review

Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss them. For this purpose, we have caught up with Etienne Drouet, Vice President of Strategic Development at SynteractHCR, an international CRO. […]

November 13, 2017 - 13 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 10 Nov 2017

Roche Partners with French Startup to Diagnose Septic Shock

In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock. Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test […]

November 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Evotec CEO Werner Lanthaler Biotech Innovation Partnerships

Interview 9 Nov 2017

Interview with Europe’s Leader in Biotech Partnerships

I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. Evotec started off as a contract research organization in Hamburg back in 1993. Today it has over 2,000 employees worldwide, its own pipeline […]

November 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Nov 2017

Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin

The ‘butterfly child’ who lost 80% of his skin has been successfully treated. The boy is now able to go to school and enjoy life with family and friends. A medical team from the Ruhr-Universität Bochum’s burn unit and the Center for Regenerative Medicine at the University of Modena have treated a boy suffering from […]

November 9, 2017 - 3 minutesmins - By Alex Dale

neurimmune ono pharmaceutical neurodegenerative disease

More News! 9 Nov 2017

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […]

November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 9 Nov 2017

Meet the Spin-Out Queen Taking on Neurological Diseases

Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […]

November 9, 2017 - 4 minutesmins - By Alex Dale

Interview 8 Nov 2017

Interviewing Europe’s Most Intense Investor about Trends in Biotech

I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday morning when I chatted with Kate Bingham, Managing Partner of SV Health Investors, formerly SV Life Sciences. Since she joined the firm in 1991, she […]

November 8, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 8 Nov 2017

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […]

November 8, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal inflammatory diseases. The company that its share will cost $15 (€13) when the company launches its IPO, […]

November 8, 2017 - 2 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

British Biotech Gets PRIME Designation for its Brittle Bones Drug

Top 5 Things to Know About Immunotherapies – A Review

Roche Partners with French Startup to Diagnose Septic Shock

Interview with Europe’s Leader in Biotech Partnerships

Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Meet the Spin-Out Queen Taking on Neurological Diseases

Interviewing Europe’s Most Intense Investor about Trends in Biotech

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!